ASTRO Release: Concurrent Use of Sorafenib and Stereotactic Body Radiotherapy for Advanced Liver Cancer Patients is Not Recommended Outside of Clinical Trials

BOSTON, Oct. 28, 2012 (GLOBE NEWSWIRE) -- Concurrent use of sorafenib and stereotactic body radiotherapy (SBRT) for advanced liver cancer patients resulted in high toxicity and is not recommended outside of clinical trials, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 54th Annual Meeting. This is the first prospective study of SBRT combined with sorafenib for hepatocellular carcinoma (HCC) patients, and initial outcomes indicate that the dose of sorafenib and the volume of tissue irradiated are key factors in the risk of toxicity; alternative sequencing of therapies should be investigated in future studies.